These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20382049)

  • 1. Topography of the masseter muscle in relation to treatment with botulinum toxin type A.
    Hu KS; Kim ST; Hur MS; Park JH; Song WC; Koh KS; Kim HJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug; 110(2):167-71. PubMed ID: 20382049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular nerve distribution of the masseter muscle as a basis for botulinum toxin injection.
    Kim DH; Hong HS; Won SY; Kim HJ; Hu KS; Choi JH; Kim HJ
    J Craniofac Surg; 2010 Mar; 21(2):588-91. PubMed ID: 20489458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of botulinum toxin type A injection into human masseter muscle on stimulated parotid saliva flow rate.
    Kwon JS; Kim ST; Jeon YM; Choi JH
    Int J Oral Maxillofac Surg; 2009 Apr; 38(4):316-20. PubMed ID: 19231136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The topographic anatomy of the masseteric nerve: A cadaveric study with an emphasis on the effective zone of botulinum toxin A injections in masseter.
    Kaya B; Apaydin N; Loukas M; Tubbs RS
    J Plast Reconstr Aesthet Surg; 2014 Dec; 67(12):1663-8. PubMed ID: 25175271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botox facial slimming/facial sculpting: the role of botulinum toxin-A in the treatment of hypertrophic masseteric muscle and parotid enlargement to narrow the lower facial width.
    Wu WT
    Facial Plast Surg Clin North Am; 2010 Feb; 18(1):133-40. PubMed ID: 20206096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between intramuscular and perimuscular injections of botulinum toxin type A.
    Campos JH; Oliveira LB; Queiroz TO; Santos KP; Freitas FM
    Aesthetic Plast Surg; 2006; 30(6):700-3; discussion 704. PubMed ID: 16977369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin A injection into corrugator muscle for frontally localised chronic daily headache or chronic tension-type headache.
    de Ru JA; Buwalda J
    J Laryngol Otol; 2009 Apr; 123(4):412-7. PubMed ID: 18588738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower facial contouring with botulinum toxin type A.
    Tartaro G; Rauso R; Santagata M; Santillo V; Itro A
    J Craniofac Surg; 2008 Nov; 19(6):1613-7. PubMed ID: 19098563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The medical management of masseteric hypertrophy with botulinum toxin.
    Finn S; Ryan P; Sleeman D
    J Ir Dent Assoc; 2000; 46(3):84-6. PubMed ID: 11323940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B; Ascher B; Fratila A; Monheit GD; Talarico S; Sterry W
    Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of botulinum toxin for the treatment of temporomandibular disorder.
    Freund B; Schwartz M
    Oral Health; 1998 Feb; 88(2):32-7. PubMed ID: 9610334
    [No Abstract]   [Full Text] [Related]  

  • 12. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
    Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
    Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on craniofacial growth and development of unilateral botulinum neurotoxin injection into the masseter muscle.
    Tsai CY; Chiu WC; Liao YH; Tsai CM
    Am J Orthod Dentofacial Orthop; 2009 Feb; 135(2):142.e1-6; discussion 142-3. PubMed ID: 19201315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of masseter hypertrophy with botulinum toxin type A.
    Al-Ahmad HT; Al-Qudah MA
    Saudi Med J; 2006 Mar; 27(3):397-400. PubMed ID: 16532107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risorius muscle: anatomic considerations with reference to botulinum neurotoxin injection for masseteric hypertrophy.
    Bae JH; Choi DY; Lee JG; Seo KK; Tansatit T; Kim HJ
    Dermatol Surg; 2014 Dec; 40(12):1334-9. PubMed ID: 25393348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin. The Newport Beach experience.
    Fulton JE
    Dermatol Surg; 1998 Nov; 24(11):1219-24. PubMed ID: 9834742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia.
    Casserly P; Timon C
    J Laryngol Otol; 2008 Jan; 122(1):52-6. PubMed ID: 17470307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
    Farahvash MR; Arad S
    J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midface lifting with botulinum toxin: intradermal technique.
    Petchngaovilai C
    J Cosmet Dermatol; 2009 Dec; 8(4):312-6. PubMed ID: 19958437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.